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• KRAS cells were more sensitive to IRE
than macrophages (BMDM and
RAW264.7).
• IRE treated KRAS* tumor cells promoted
macrophage migration. This was
confirmed in in vivo experiment, which
showed increased tumor infiltration of
CD169+ macrophages 24h after IRE.
• PH252 PDAC tumors injected into the
spleen metastasized to the liver.

Conclusion

• IRE decreased cell proliferation of tumor
cells and influenced macrophage
migration. Because of IRE's effects on
macrophages, further studies on the
impact of IRE on presentation of tumor
associated antigens are warranted.

Future Directions

• Test IRE effects at other voltages and with
other cell types
• Refine tumor model by injecting fewer cells
or injecting directly to pancreas
• Characterize the effects of local IRE
treatment on liver metastasis
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Fig. 5. 2 million cell injection of PH252 PDC
into spleen with liver metastasis. a,c Coronal
view at 1 and 2 weeks, respectively. b,d axial
view at 1 and 2 weeks, respectively. e Liver
(left) and spleen (right) of mouse following
death 2.5 weeks after injection. Stars placed
to bottom right of tumor
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Fig. 1 in vitro methods. IRE treat KRAS cells,
RAW264.7 macrophages, or Bone Marrow Derived
Macrophages (BMDM) with 20 pulses, 0.1 ms long,
1 second between pulses, at 300 or 400 V.
a. Plate cells to 96-well plate and incubate
for 24 hours. Then do MTS cell
proliferation assay to determine cell
concentration.
b. Place macrophages on top of membrane
and KRAS tumor cells below. Incubate 6
hours for migration before fixation and
staining
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Fig. 3. Assessing impact of IRE treated KRAS
cells on macrophage migration. a,b
Representative images of RAW264.7 migration
following 6 hours with control (a) or 400V (b) IRE
treated KRAS cells. c Bar graph of means and
standard deviations of number of cells migrated
per field of view. *** p<0.001 (one-way ANOVA)
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Methods
IRE-treated Cells: KRAS* PDAC cells,
murine RAW264.7 macrophages, and murine
bone marrow derived macrophages (BMDM)
were used in following assays.
Assays: MTS assay assessed cell
proliferation following IRE. Transwell
migration assessed if IRE treated KRAS*
cells affected macrophage migration (Fig. 1)
Immunofluorescence (IF) staining: IF
staining assessed the density of
CD169+ macrophages on KRAS* tumor
tissues from non-treated and IRE treated
mice.
Liver metastasis model: PH252 cells (a
variant of KRAS* PDAC cells) were
inoculated into the spleen of mice to develop
a liver metastasis model of PDAC. Tumor
growth was monitored by T2-weighted MRI.
Statistics: Significance was determined by
one-way ANOVA with p≤0.05 considered
statistically significant.
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• Irreversible electroporation (IRE) causes
irreversible permeabilization of the cell
membrane via short high-voltage electric
pulses.
• IRE offers a promising treatment modality
for local ablation of pancreatic ductal
adenocarcinoma (PDAC).
• We aim to assess preclinical effects IRE
on different types of cells in vitro and
macrophage infiltration in vivo.
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Fig. 6. 0.5 million cell injection of PH252 PDC
into spleen with liver metastasis. a,c,e Coronal
view at 1, 2, and 3 weeks, respectively. b,d,f
axial view at 1, 2, and 3 weeks, respectively. g
Liver (left) and spleen (right) of mouse
following death 3.5 weeks after injection. Stars
placed to bottom right of tumor
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Fig. 2 Cell Proliferation after IRE treatment 24h.
KRAS, RAW264.7, and Bone Marrow Derived
Macrophages (BMDM) were treated with IRE at 0,
300, or 400 V. Cell concentration was calculated
using MTS proliferation assay and is displayed as
percentage of control proliferation.
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Fig. 4. IF staining of KRAS tumor tissue with
DAPI (nuclear, blue) and CD169 (Macrophages,
green). a,b control and IRE treated tumors,
respectively. c Bar graph of number of
macrophages counted per field of view ***
p<0.0001 (one-way ANOVA)
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